Stockscreener 앱 받기
54.73
3.13%
1.66
전일 마감가:
$53.07
열려 있는:
$53.2
하루 거래량:
994.85K
Relative Volume:
1.00
시가총액:
$4.41B
수익:
-
순이익/손실:
$-64.16M
주가수익비율:
-43.09
EPS:
-1.2702
순현금흐름:
$-69.06M
1주 성능:
+0.98%
1개월 성능:
+44.60%
6개월 성능:
+109.85%
1년 성능:
+88.08%
1일 변동 폭
$52.17
$55.17
1주일 범위
$51.58
$56.80
52주 변동 폭
$14.80
$57.40
Cg Oncology Inc Stock (CGON) Company Profile
명칭
Cg Oncology Inc
전화
(949) 419-6203
주소
400 SPECTRUM CENTER DRIVE, IRVINE
CGON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
54.73 | 4.28B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 개시 | Wedbush | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-08 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-05-02 | 개시 | JP Morgan | Overweight |
| 2025-04-16 | 개시 | Scotiabank | Sector Perform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-23 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2024-06-28 | 개시 | BofA Securities | Buy |
| 2024-02-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-20 | 개시 | Goldman | Neutral |
| 2024-02-20 | 개시 | Morgan Stanley | Overweight |
| 2024-02-14 | 개시 | H.C. Wainwright | Buy |
모두보기
Cg Oncology Inc 주식(CGON)의 최신 뉴스
Investment Review: Can CG Oncology Inc sustain earnings growthEarnings Performance Report & High Win Rate Trade Tips - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Revenue Check: Is CG Oncology Inc stock a hidden gemRate Hike & Risk Managed Investment Signals - baoquankhu1.vn
Gainers Report: Is Citigroup Capital XVI Preferred Security stock undervalued right nowEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
CGON: Pivotal data and regulatory milestones position a novel NMIBC therapy for major market expansion - TradingView — Track All Markets
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
CG Oncology Expands At-The-Market Equity Offering Capacity - The Globe and Mail
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026 - Intellectia AI
Why CG Oncology Stock Is Suddenly Climbing Higher - TipRanks
Travel Stocks: What is the target price for CG Oncology Inc stock2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Aug Highlights: Will CG Oncology Inc outperform the market in YEARPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com India
Mulay, James sells CG Oncology (CGON) shares for $584,798 - Investing.com
CG Oncology files amendment to increase stock offering to $550 million By Investing.com - Investing.com Nigeria
James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock - MarketBeat
CG Oncology files amendment to increase stock offering to $550 million - Investing.com
CG Oncology Files Amendment to Increase Stock Offering - TradingView — Track All Markets
Aug Spikes: Is Skeena Resources Limited attractive for institutional investorsDollar Strength & Weekly Top Stock Performers List - baoquankhu1.vn
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - MSN
Institution Moves: Why analysts upgrade CG Oncology Inc. stockJuly 2025 Fed Impact & AI Enhanced Trading Signals - Bộ Nội Vụ
Truist Securities raises CG Oncology stock price target to $66 on early trial data - Investing.com Canada
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
CG Oncology Expedites PIVOT-006 Phase 3 Topline Data Readout In Intermediate-Risk NMIBC To H1 2026 - Nasdaq
CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week - TechStock²
CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next - TechStock²
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next - TechStock²
Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum - Sahm
CG Oncology accelerates timeline for bladder cancer trial data By Investing.com - Investing.com Nigeria
Cg Oncology stock hits 52-week high at 46.19 USD By Investing.com - Investing.com Nigeria
Is CG Oncology Inc. stock supported by strong cash flowsJuly 2025 Setups & High Accuracy Swing Trade Signals - Улправда
CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 TimelineHas The Bull Case Changed? - Yahoo Finance
Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? - Yahoo Finance
CG Oncology’s Bladder Cancer Bet Heads Toward A Big 2026 Test - Finimize
Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating - TipRanks
CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise - StocksToTrade
CG Oncology Price Target Raised Amid Robust Market Prospects - timothysykes.com
CG Oncology stock price target raised to $93 from $89 at Morgan Stanley - Investing.com Canada
Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology - TipRanks
CG Oncology rises after expediting a late-stage trial readout for lead asset - Seeking Alpha
Midday Stock Roundup: loanDepot Rises on Trump Move - Orange County Business Journal
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026 - TechStock²
CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target - TipRanks
CG Oncology to Share Data From Phase 3 Bladder Cancer Trial a Year Ahead of Schedule; Shares Up - marketscreener.com
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighTime to Buy? - MarketBeat
CG Oncology Stock Boosted by Price Target Increase - timothysykes.com
Is Accelerated PIVOT-006 Data for Cretostimogene Reshaping the Investment Case for CG Oncology (CGON)? - Sahm
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
CG Oncology stock soars after Phase 3 trial data timeline accelerated - Investing.com Nigeria
Cg Oncology Inc (CGON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):